venetoclax + azacitidine +/- donor lymphocyte infusion
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout venetoclax + azacitidine +/- donor lymphocyte infusion
venetoclax + azacitidine +/- donor lymphocyte infusion is a phase 1/2 stage product being developed by AbbVie for MDS. The current trial status is active. This product is registered under clinical trial identifier NCT05226455. Target conditions include MDS, AML.
What happened to similar drugs?
0 of 5 similar drugs in MDS were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05226455 | Phase 1/2 | Active |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 32 |
| KRN321 | Kyowa Kirin | Phase 2 | 35 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 29 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 44 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 21 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 29 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 27 |
| Panobinostat | Novartis | Phase 2 | 27 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 27 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 28 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 29 |
| Panobinostat | Novartis | Phase 1 | 29 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 27 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 27 |
| Placebo + Romiplostim | Amgen | Phase 2 | 35 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 40 |
| Darbepoetin Alfa | Amgen | Phase 3 | 40 |